Metrics as of 10/17/2026, 08:28 AM (Berlin time), refresh in progress.
IGC Pharma Stock
IGC Pharma, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Ram Mukunda
- Employees
- 70
- Market cap
- $25 M
- IPO
- 24/05/2006
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2…
IGC Pharma stock: price history
1D
-3.2%
1W
-12.1%
1M
-9.6%
6M
-26.8%
YTD
-12.6%
1Y
-38.7%
2Y
-39.6%
5Y
-83.2%
10Y
-38.5%
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~39% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about IGC Pharma
Analyst assessment of IGC Pharma
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 26/08/2026
IGC Pharma stock metrics
P/E
-2.99
P/B
4.03
EV/EBITDA
-3.52
RETURN ON EQUITY
-47.9%
NET MARGIN
-1,107.9%
DEBT/EQUITY
0.18
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
86.8%
FLOAT SHARES
89,719,744
AVG. DAILY VOLUME (30D)
635,618
Insider transactions (SEC)
GRIMALDI CLAUDIA
Mukunda Ram
Mukunda Ram
GRIMALDI CLAUDIA
Mukunda Ram
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about IGC Pharma stock
What does IGC Pharma do?
IGC Pharma, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Ram Mukunda, the company employs around 70 people.
The IPO was on 24/05/2006; the stock trades on AMEX under the ticker IGC.
What do analysts say about IGC Pharma stock?
2 analysts rate the stock, the consensus is Buy (as of 26/08/2026).
This is an external assessment, not a statement by Market Jury.
When does IGC Pharma report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly -39% stronger than usual.
Does IGC Pharma pay a dividend?
No, IGC Pharma currently does not pay a dividend.
Which stocks are comparable to IGC Pharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get IGC Pharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess IGC Pharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.